The story of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated massive profits, the end of its exclusive rights opened the floodgates to generic https://cyrusfwzy195392.blog-gold.com/59890990/the-copyright-and-pharma-a-volatile-opportunity